Eckert & Ziegler - Radiation Therapy Specialist Benefits from Increasing Treatment Numbers!
Reading Time: 1 minute
Business Driver: Eckert & Ziegler benefits as a provider of pharmaceutical radioisotopes such as Gallium-68 (diagnostic isotope), Lutetium-177, Actinium-225, and Yttrium-90, capitalizing on the triumph of radiation therapy in treating serious illnesses like cancer. In the first half of the year, the company achieved a 2% increase in revenue to €148.8 million and a 9% improvement in adjusted operating profit (EBIT) to €35.4 million, primarily benefiting from strong growth in pharmaceutical radioisotopes. The annual forecast, which anticipates...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
